Navigation Links
The aorta is torn apart in the Marfan syndrome
Date:7/17/2008

A severe complication of the Marfan syndrome is that the aorta may split and be torn apart. The patient can be protected if the syndrome is diagnosed and treated in good time. In the current edition of the Deutsches rzteblatt International (Dtsch Arztebl Int 2008; 105[27]: 483-91), the human geneticist Mine Arslan-Kirchner from Hannover University Medical School and his coauthors present additional studies on Marfan patients.

http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=60813

Marfan syndrome occurs at a frequency of between 1:5000 and 1:10000 and is either hereditary or the result of spontaneous genetic mutations. As a consequence, there are changes in the consistency of connective tissue. Symptoms develop in the cardiovascular system, the eyes, and the skeleton. A much feared and potentially fatal complication is that the aorta can split and tear. The patient can then die from internal bleeding. Patients' average life expectancy is 32 years without treatment, but can be extended to 60 years with optimal therapy. The full-blown disease is not always present; individual symptoms may be lacking. This makes reliable diagnosis difficult and in many cases, clinical and molecular genetic studies must be combined to clarify the situation. If the diagnosis is made in good time, the damaged aorta can be surgically replaced.


'/>"/>

Contact: Elke Bartholomaeus
bartholomaeus@aerzteblatt.de
49-223-470-11133
Deutsches Aerzteblatt International
Source:Eurekalert

Page: 1

Related biology news :

1. After more than 100 years apart, webworms devastate New Zealand parsnips
2. Gene regulation, not just genes, is what sets humans apart
3. Researchers discover gene for branchio-oculo-facial syndrome
4. Study suggests new way to screen infants for fetal alcohol syndrome
5. Effective ADHD treatment found for children with fragile X syndrome
6. Rare cancer-causing syndrome found, for the first time, in Singapore
7. Obesity-related hormone is higher in children with Down syndrome
8. Restless legs syndrome affects nearly 2 percent of US/UK children
9. Researchers identify proteins involved in new neurodegenerative syndrome
10. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology: